List of Zolinza drug patents
Zolinza is owned by Merck.
Zolinza contains Vorinostat.
Zolinza has a total of 9 drug patents out of which 4 drug patents have expired.
Expired drug patents of Zolinza are:
- US7652069
- US8101663
- US7732490
- US8067472
Zolinza was authorised for market use on 06 October, 2006.
Zolinza is available in capsule;oral dosage forms.
Zolinza can be used as treatment of cutaneous manifestations in patients wtih cutaneous t-cell lymphoma (ctcl).
The generics of Zolinza are possible to be released after 18 March, 2028.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7456219 | MERCK | Polymorphs of suberoylanilide hydroxamic acid |
Mar, 2027
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7652069 | MERCK | Polymorphs of suberoylanilide hydroxamic acid |
Mar, 2023
(29 days ago) | |
| US8101663 | MERCK | Polymorphs of suberoylanilide hydroxamic acid |
Mar, 2023
(29 days ago) | |
| US7732490 | MERCK | Methods of treating cancer |
Mar, 2023
(29 days ago) | |
| US8067472 | MERCK | Methods of treating Hodgkin's and non-Hodgkin's lymphoma |
Mar, 2023
(29 days ago) | |
| US7851509 | MERCK | Polymorphs of suberoylanilide hydroxamic acid |
Feb, 2024
(10 months from now) | |
| US7399787 | MERCK | Methods of treating cancer with HDAC inhibitors |
Feb, 2025
(1 year, 10 months from now) | |
| US8093295 | MERCK | Formulations of suberoylanilide hydroxamic acid and methods for producing the same |
May, 2026
(3 years from now) | |
| US8450372 | MERCK | Formulations of suberoylanilide hydroxamic acid and methods for producing same |
Mar, 2028
(4 years from now) | |
Drugs and Companies using VORINOSTAT ingredient
Market Authorisation Date: 06 October, 2006
Treatment: Treatment of cutaneous manifestations in patients wtih cutaneous t-cell lymphoma (ctcl)
Dosage: CAPSULE;ORAL
ZOLINZA family patents
34
United States
10
European Union
9
Australia
9
Japan
8
New Zealand
7
China
6
Canada
5
Russia
5
Korea, Republic of
4
South Africa
4
Norway
3
Brazil
3
Poland
2
Israel
2
Mexico
2
Morocco
2
Argentina
2
Spain
2
Taiwan, Province of China
2
Ecuador
2
Ukraine
1
Denmark
1
Austria
1
Hong Kong
1
Slovenia
1
Costa Rica
1
Germany
1
Croatia
1
Portugal
1
Cyprus
1
Malaysia
1
Dominican Republic
1
Peru
1
Iceland
1
Nicaragua
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic